Docetaxel for Metastatic Pancreatic Cancer
Author Information
Author(s): Okada S, Sakata Y, Matsuno S, Kurihara M, Sasaki Y, Ohashi Y, Taguchi T
Primary Institution: National Cancer Center Hospital
Hypothesis
This study aimed to evaluate the activity and toxicity of moderate-dose docetaxel in Japanese chemo-naive patients with measurable metastatic pancreatic cancer.
Conclusion
Docetaxel did not show significant anti-tumour activity in patients with metastatic pancreatic cancer.
Supporting Evidence
- The median survival time for all patients was 118 days.
- The main grade 3–4 toxicities included leucocytopenia (67%) and neutropenia (86%).
- None of the patients achieved an objective response.
Takeaway
The study tested a drug called docetaxel on patients with pancreatic cancer, but it didn't help them get better.
Methodology
Patients received docetaxel intravenously every 3–4 weeks, with dose adjustments based on observed toxic effects.
Limitations
The study had a small sample size and no patients achieved an objective response.
Participant Demographics
Japanese chemo-naive patients with measurable metastatic pancreatic cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website